Sanofi: FDA approves asthma drug
(CercleFinance.com) - Sanofi reports that the US FDA has approved Dupixent (dupilumab) for the adjunct treatment of moderate-to-severe asthma with an eosinophilic phenotype or oral corticosteroid-dependent asthma in children aged 6 to 11.
Asthma is one of the most common illnesses in children. About 75,000 children between the ages of six and 11 have moderate-to-severe uncontrolled asthma in the United States, as do many more children elsewhere in the world.
FDA approval was based on data from a phase III trial that evaluated the efficacy and safety of Dupixent, in combination with standard asthma therapy, in children with moderate-to-severe uncontrolled asthma.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
Asthma is one of the most common illnesses in children. About 75,000 children between the ages of six and 11 have moderate-to-severe uncontrolled asthma in the United States, as do many more children elsewhere in the world.
FDA approval was based on data from a phase III trial that evaluated the efficacy and safety of Dupixent, in combination with standard asthma therapy, in children with moderate-to-severe uncontrolled asthma.
Copyright (c) 2021 CercleFinance.com. All rights reserved.